CME

Host: Adam Brufsky, MD, PhD This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.

Host: Christopher M. Gallagher, MD This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.

Host: Adam Brufsky, MD, PhD This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.

Host: Adam Brufsky, MD, PhD Host: Christopher M. Gallagher, MD This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.

Host: Adam Brufsky, MD, PhD Host: Christopher M. Gallagher, MD This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.

Host: Christopher M. Gallagher, MD Host: Adam Brufsky, MD, PhD This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.

Host: Lee Shulman MD, FACOG, FACMG Guest: Kristina Deligiannidis, MD The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD.

Host: Jessica Ailani, MD Guest: Dawn C. Buse, PhD Upwards of 47 million people in the U.S. suffer from migraines, often accompanied by widespread personal, professional, and social disabilities. Though a similar prevalence is initially observed between men and women, by mid-adulthood the prevalence of migraine is 3-fold greater in women than men. Newer agents, both injectable and oral and focused on modulating the calcitonin gene-related peptide pathway, have emerged and have proven highly effective in managing both acute and chronic migraine. Join Drs. Jessica Ailani and Dawn Buse as they provide an overview of the changing landscape of migraine therapy, especially as it impacts women across different life-stages.

Host: Pranshu Mohindra, MD Guest: Melissa Teply, MD Guest: Judith Paice, PhD, RN Guest: Fionnuala Crowley, MD This enduring program of the live-virtual symposium will focus on the challenges of managing cancer pain using the Evolve KOL Knockout™ case-based format. The key opinion leaders (KOLs) will be challenged by the host/moderator to diagnose and manage patient scenarios with varying levels of difficulty. Learners will vote on the winner of each case presentation round and the moderator will declare a match winner at the conclusion. There will be learning, laughter, and only one KOL left standing!

Host: Stefan D. Anker, MD, PhD Guest: John Cleland, MD Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA Iron deficiency is a common heart failure comorbidity with a negative impact on patients’ quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions?

Host: Ticiana Leal, MD Host: Jacob Sands, MD In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.

Host: Ticiana Leal, MD Host: Jacob Sands, MD In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.

Host: Ticiana Leal, MD Host: Jacob Sands, MD In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.

Host: Ticiana Leal, MD Host: Jacob Sands, MD In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.

Host: Ticiana Leal, MD Host: Jacob Sands, MD In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.